Pharma Journalist -

UCB, a global biopharmaceutical company, announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s…
Read More...

BeiGene, Ltd. announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to BGB-16673, an orally available investigational Bruton’s tyrosine kinase…
Read More...

As BioNTech, Moderna, and Merck have recently released positive phase II clinical results for personalized cancer vaccines, the whole industry is now racing to develop affordable and…
Read More...

The race for clinical approval of TGF-β therapies is heating up, fueled by significant investments like Corbus Pharmaceuticals' recent $98.5 million and Biacara Therapeutics' $165…
Read More...

ENHERTU (fam-trastuzumab deruxtecan-nxki) has been granted Breakthrough Therapy Designation (BTD) in the U.S. for the treatment of unresectable or metastatic hormone receptor positive…
Read More...

PANTHERx Rare, a leader in rare disease product patient access and support services in the United States, is pleased to announce it is partnering with Gilead Sciences, Inc. for the…
Read More...

Eli Lilly and Company announced the opening of the Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport dedicated to advancing Lilly's…
Read More...

Incyte and Syndax Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, for the treatment of…
Read More...

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Livdelzi (seladelpar) for the treatment of primary biliary…
Read More...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has received conditional approval in China as a monotherapy for the treatment of adult patients with locally advanced…
Read More...